5622-36-6

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 6-QUINOLINEACETATE is used as a reactuant for the preparation of triazolopyridazines, which are known as tyrosine kinase modulators. These modulators play a crucial role in the regulation of cellular processes, including cell growth, differentiation, and apoptosis. They have potential applications in the treatment of various diseases, particularly cancer, by targeting specific tyrosine kinase enzymes involved in the development and progression of the disease.

InChI:InChI=1/C12H11NO2/c1-15-12(14)8-9-4-5-11-10(7-9)3-2-6-13-11/h2-7H,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 5622-34-4 6-quinoline acetic acid 
• 1197-55-3 4-aminophenylacetic acid 

Downstream Products

• 227809-77-0 2-(quinolin-6-yl)ethan-1-ol 
• 5622-50-4 methyl 2-(1,2,3,4-tetrahydroquinolin-6-yl)acetate 

Relevant academic research and scientific papers

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors

Herein, we report a novel series of highly potent and selective triazolothiadiazole c-Met inhibitors. Starting with molecule 5, we have applied structure-based drug design principles to identify the triazolothiadiazole ring system. We successfully replaced the metabolically unstable phenolic moiety with a quinoline group. Further optimization around the 5,6 bicyclic moiety led to the identification of 21. Compound 21 suffered from PDE3 selectivity issues and subsequent, structurally informed design led to the discovery of compound 23. Compound 23 has exquisite kinase selectivity, excellent potency, favorable ADME profile, and showed dose-dependent antitumor efficacy in a SNU-5 gastric cancer xenograft model.

FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS

The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3- b ]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-met with high protein kinase selectivity but broad phosphodiesterase family inhibition lea

The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-

A TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE

The present invention relates to compound (1), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound (1) and methods of using the compositions in the treatment of proliferative disorders.

HETEROCYCLIC KINASE MODULATORS

The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.

TRIAZOLOPYRIDAZINE DERIVATIVES

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R3' are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula (I).